Generic Vizz Availability
Last updated on Sep 10, 2025.
Vizz is a brand name of aceclidine ophthalmic, approved by the FDA in the following formulation(s):
VIZZ (aceclidine hydrochloride - solution/drops;ophthalmic)
-
Manufacturer: LENZ THERAP
Approval date: July 31, 2025
Strength(s): EQ 1.44% BASE [RLD]
Is there a generic version of Vizz available?
No. There is currently no therapeutically equivalent version of Vizz available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vizz. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions and methods for the treatment of presbyopia
Patent 10,052,313
Issued: August 21, 2018
Inventor(s): Horn; Gerald et al.
Assignee(s): PRESBYOPIA THERAPIES, LLC (Coronado, CA)The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine and a polyol. The compositions optionally contain a cycloplegic agent, a surfactant, a viscosity enhancer, an osmolarity modifier and a preservative.
Patent expiration dates:
- March 24, 2034✓✓
- March 24, 2034
-
Compositions and methods for the treatment of presbyopia
Patent 11,179,328
Issued: November 23, 2021
Inventor(s): Horn; Gerald
Assignee(s): LENZ THERAPEUTICS, INC. (Rancho Santa Fe, CA)The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.
Patent expiration dates:
- March 24, 2034✓
- March 24, 2034
-
Compositions and methods for storage stable ophthalmic drugs
Patent 12,128,036
Issued: October 29, 2024
Inventor(s): Horn; Gerald
Assignee(s): LENZ THERAPEUTICS OPERATIONS, INC. (Solana Beach, CA)The present invention is related to methods of stabilizing an ophthalmic drug by adding a surfactant and a viscosity enhancer to the ophthalmic drug to create a composition wherein the composition has a viscosity of about 25 centipoise or less at a shear rate of 1/1000 per second at 25 degrees Celsius and a viscosity of about 70 centipoise or more at shear rate of 1 per second at 25 degrees Celsius, filling the composition into a container; and storing the container at a temperature from about 2 degrees Celsius to about 25 degrees Celsius. The present invention is further directed to a container prepared by the methods of the present invention.
Patent expiration dates:
- October 8, 2039✓
- October 8, 2039
-
Compositions and methods for the treatment of presbyopia
Patent 9,844,537
Issued: December 19, 2017
Inventor(s): Horn; Gerald et al.
Assignee(s): Presbyopia Therapies LLC (Coronado, CA)The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine and a polyol. The compositions optionally contain a cycloplegic agent, a surfactant, a viscosity enhancer, an osmolarity modifier and a preservative.
Patent expiration dates:
- March 24, 2034✓✓
- March 24, 2034
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- July 31, 2030 - NEW CHEMICAL ENTITY
More about Vizz (aceclidine ophthalmic)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Dosage information
- FDA approval history
- Drug class: miscellaneous ophthalmic agents
- En español
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.